Literature DB >> 7787249

Annexin II marks astrocytic brain tumors of high histologic grade.

B J Roseman1, A Bollen, J Hsu, K Lamborn, M A Israel.   

Abstract

Annexin II is highly expressed in glioblastoma multiforme [Reeves, S. A.; Chavez-Kappel, C.; Davis, R.; Rosenblum, M.; Israel, M. A. Developmental regulation of annexin II (lipocortin 2) in human brain and expression in high grade glioma. Cancer Res. 52:6871-6876; 1992] and is a likely second messenger in mitogenic pathways known to be important for the growth of these tumors. We have examined tumor tissue from patients diagnosed with low-, intermediate-, or high-grade astrocytic tumors for expression of annexin II by immunohistochemistry, and found that annexin II levels varied significantly among these three tumors (P < 0.0005). Levels were highest in glioblastoma multiforme, intermediate in anaplastic astrocytomas, and lowest in astrocytomas. In contrast to the usual cytoplasmic localization of annexin II, distinct nuclear staining was found in many of the specimens. Reactive astrocytes found in gliotic brain also stained with anti-annexin II antibody. We examined matched specimens for a correlation between annexin II staining intensity and the bromodeoxyuridine labeling index and found that, while tumors with the most intense annexin II staining had highest bromodeoxyuridine labeling indexes, there was not a strong association between these two parameters. The association between annexin II staining and histologic grade in astrocytic malignancies indicates that annexin II may be an important marker of high-grade glial tumors, and suggests that this marker may be useful for the pathologic classification of glial tumors and the clinical evaluation of brain tumor patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7787249

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  24 in total

1.  Comparison of annexin II, p63 and alpha-methylacyl-CoA racemase immunoreactivity in prostatic tissue: a tissue microarray study.

Authors:  Jocelyn Stewart; Neil Fleshner; Heather Cole; Joan Sweet
Journal:  J Clin Pathol       Date:  2006-08-17       Impact factor: 3.411

2.  Down-regulation of annexin A10 in hepatocellular carcinoma is associated with vascular invasion, early recurrence, and poor prognosis in synergy with p53 mutation.

Authors:  Shu-Hsiang Liu; Chiao-Ying Lin; Shian-Yang Peng; Yung-Ming Jeng; Hung-Wei Pan; Po-Lin Lai; Chao-Lien Liu; Hey-Chi Hsu
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

3.  Clinical and prognostic role of annexin A2 in adamantinomatous craniopharyngioma.

Authors:  Yuelong Wang; Jiaojiao Deng; Gang Guo; Aiping Tong; Xirui Peng; Haifeng Chen; Jianguo Xu; Yi Liu; Chao You; Liangxue Zhou
Journal:  J Neurooncol       Date:  2016-09-17       Impact factor: 4.130

4.  Homing of cancer cells to the bone.

Authors:  Anjali Mishra; Yusuke Shiozawa; Kenneth J Pienta; Russell S Taichman
Journal:  Cancer Microenviron       Date:  2011-08-09

5.  Annexin A2 is a molecular target for TM601, a peptide with tumor-targeting and anti-angiogenic effects.

Authors:  Kamala Kesavan; Judson Ratliff; Eric W Johnson; William Dahlberg; John M Asara; Preeti Misra; John V Frangioni; Douglas B Jacoby
Journal:  J Biol Chem       Date:  2009-12-15       Impact factor: 5.157

6.  Expression of annexin II in conventional renal cell carcinoma is correlated with Fuhrman grade and clinical outcome.

Authors:  U Zimmermann; C Woenckhaus; S Pietschmann; H Junker; S Maile; K Schultz; C Protzel; J Giebel
Journal:  Virchows Arch       Date:  2004-08-26       Impact factor: 4.064

Review 7.  Annexin A2 system in human biology: cell surface and beyond.

Authors:  Min Luo; Katherine A Hajjar
Journal:  Semin Thromb Hemost       Date:  2013-03-12       Impact factor: 4.180

8.  Cross-reactivity between annexin A2 and Beta-2-glycoprotein I in animal models of antiphospholipid syndrome.

Authors:  R Weiss; A Bitton; L Nahary; M T Arango; I Benhar; M Blank; Y Shoenfeld; J Chapman
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

9.  Glycogen synthase kinase-3 and Omi/HtrA2 induce annexin A2 cleavage followed by cell cycle inhibition and apoptosis.

Authors:  Chi-Yun Wang; Yee-Shin Lin; Wu-Chou Su; Chia-Ling Chen; Chiou-Feng Lin
Journal:  Mol Biol Cell       Date:  2009-08-05       Impact factor: 4.138

10.  iTRAQ-based proteomics profiling reveals increased metabolic activity and cellular cross-talk in angiogenic compared with invasive glioblastoma phenotype.

Authors:  Uros Rajcevic; Kjell Petersen; Jaco C Knol; Maarten Loos; Sébastien Bougnaud; Oleg Klychnikov; Ka Wan Li; Thang V Pham; Jian Wang; Hrvoje Miletic; Zhao Peng; Rolf Bjerkvig; Connie R Jimenez; Simone P Niclou
Journal:  Mol Cell Proteomics       Date:  2009-08-12       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.